Mizuho Reiterates Neutral on Syneos Health, Maintains $38 Price Target
Mizuho analyst Ann Hynes reiterates Syneos Health (NASDAQ:SYNH) with a Neutral and maintains $38 price target.
Credit Suisse Reiterates Outperform on AMN Healthcare Services, Maintains $147 Price Target
Credit Suisse analyst Jonathan Yong reiterates AMN Healthcare Services (NYSE:AMN) with a Outperform and maintains $147 price target.
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $36 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $36 price target.
Needham Reiterates Buy on Cara Therapeutics, Maintains $26 Price Target
Needham analyst Joseph Stringer reiterates Cara Therapeutics (NASDAQ:CARA) with a Buy and maintains $26 price target.
Needham Reiterates Buy on DraftKings, Maintains $20 Price Target
Needham analyst Bernie McTernan reiterates DraftKings (NASDAQ:DKNG) with a Buy and maintains $20 price target.
HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $32 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $32 price target.
HC Wainwright & Co. Reiterates Buy on Inozyme Pharma, Maintains $20 Price Target
HC Wainwright & Co. analyst Edward White reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $20 price target.
HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $25 Price Target
HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $25 price target.
Needham Reiterates Buy on Sage Therapeutics, Maintains $70 Price Target
Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) with a Buy and maintains $70 price target.
Telsey Advisory Group Reiterates Outperform on Bath & Body Works, Maintains $52 Price Target
Telsey Advisory Group analyst Dana Telsey reiterates Bath & Body Works (NYSE:BBWI) with a Outperform and maintains $52 price target.